CN Patent

CN114679906A — 向具有重度肾损伤的患者施用特定的vmat2抑制剂的方法

Assigned to Neurocrine Biosciences Inc · Expires 2022-06-28 · 4y expired

What this patent protects

提供了对有需要的个体施用囊泡单胺转运体2(VMAT2)抑制剂的方法，其中所述个体具有重度肾损伤。

USPTO Abstract

提供了对有需要的个体施用囊泡单胺转运体2(VMAT2)抑制剂的方法，其中所述个体具有重度肾损伤。

Drugs covered by this patent

valbenazine-tosylate (VALBENAZINE TOSYLATE)

Patent Metadata

Patent number: CN114679906A
Jurisdiction: CN
Classification: —
Expires: 2022-06-28
Drug substance claim: No
Drug product claim: No
Assignee: Neurocrine Biosciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.